BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38702998)

  • 1. Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation.
    Chow S; Lee S; Lin A; Craddock KJ; Smith AC; Tsui H
    Br J Haematol; 2024 May; ():. PubMed ID: 38702998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
    Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
    Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
    Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
    Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
    González-López O; Muñoz-González JI; Orfao A; Álvarez-Twose I; García-Montero AC
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.
    Traina F; Visconte V; Jankowska AM; Makishima H; O'Keefe CL; Elson P; Han Y; Hsieh FH; Sekeres MA; Mali RS; Kalaycio M; Lichtin AE; Advani AS; Duong HK; Copelan E; Kapur R; Olalla Saad ST; Maciejewski JP; Tiu RV
    PLoS One; 2012; 7(8):e43090. PubMed ID: 22905207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic mastocytosis with myeloid sarcoma and B-CLL: molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature.
    Decruyenaere P; Mazure D; Moors I; Van Dorpe J; Van der Linden M; Denys B; Hofmans M; Offner F
    Acta Clin Belg; 2023 Feb; 78(1):58-66. PubMed ID: 35098906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.
    Hoermann G; Sotlar K; Jawhar M; Kristensen T; Bachelot G; Nedoszytko B; Carter MC; Horny HP; Bonadonna P; Sperr WR; Hartmann K; Brockow K; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Triggiani M; Butterfield JH; Schwaab J; Reiter A; Gotlib J; Metcalfe DD; George TI; Orfao A; Valent P; Arock M
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1953-1963. PubMed ID: 35283331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis.
    Balci TB; Prykhozhij SV; Teh EM; Da'as SI; McBride E; Liwski R; Chute IC; Leger D; Lewis SM; Berman JN
    Br J Haematol; 2014 Oct; 167(1):48-61. PubMed ID: 24989799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the KIT
    Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA
    Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature.
    Bernd HW; Sotlar K; Lorenzen J; Osieka R; Fabry U; Valent P; Horny HP
    J Clin Pathol; 2004 Mar; 57(3):324-8. PubMed ID: 14990611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
    Valent P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
    Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
    Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
    Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
    J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
    Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini RM; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
    EBioMedicine; 2019 May; 43():150-158. PubMed ID: 30975542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis.
    Veitch S; Radia DH
    Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
    Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
    Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
    Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
    Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
    Pullarkat ST; Wu W; Pullarkat V
    Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis.
    Kristensen T; Vestergaard H; Bindslev-Jensen C; Mortz CG; Kjaer HF; Ollert M; Møller MB; Broesby-Olsen S;
    Allergy; 2017 Nov; 72(11):1737-1743. PubMed ID: 28432683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.